Estrogen replacement therapy after coronary angioplasty in women
JH O'Keefe Jr,
SC Kim,
RR Hall,
VC Cochran,
SL Lawhorn,
and
BD McCallister
Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri, USA.
OBJECTIVES: The purpose of this study was to assess the effects of estrogen replacement therapy on long-term outcome, including restenosis, myocardial infarction, stroke and death after a first percutaneous transluminal coronary angioplasty (PTCA) procedure, in postmenopausal women. BACKGROUND: Observational and epidemiologic studies, basic laboratory research and clinical trials consistently suggest that estrogen replacement therapy is associated with beneficial cardiovascular effects in women. These cardioprotective actions may be particularly relevant to women with coronary artery disease, such as those who have undergone PTCA. METHODS: This was a retrospective study that included 337 women who underwent elective PTCA between 1982 and 1994. The treatment group consisted of 137 consecutive women receiving long-term estrogen therapy at the time of elective PTCA and during follow-up. The control group comprised 200 women who were computer-matched with the estrogen group. The mean follow-up period was 65 +/- 35 months. RESULTS: Actuarial survival was superior in the estrogen group; the 7-year survival rate was 93% for the estrogen group versus 75% for the control group (p = 0.001). The cardiovascular event rate (death, nonfatal myocardial infarction or nonfatal stroke) was significantly lower in the estrogen group at 7 years (12% vs. 35% in the control group, p = 0.001). The need for subsequent revascularization during follow-up was similar in the two groups. Multivariable analysis identified diabetes, estrogen therapy (adjusted risk ratio 0.38, 95% confidence interval 0.19 to 0.79) and left ventricular ejection fraction < 40% as independent correlates of cardiovascular death or myocardial infarction during follow-up. CONCLUSIONS: Estrogen replacement therapy was associated with an improved long-term outcome after PTCA in postmenopausal women.
This article has been cited by other articles:
|
|
|
|
 
I. C Villar, A. J Hobbs, and A. Ahluwalia
Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor
J. Endocrinol.,
June 1, 2008;
197(3):
447 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sitges, V. A. Teijeira, A. Scalise, B. Vidal, D. Tamborero, B. Collvinent, S. Rivera, I. Molina, M. Azqueta, C. Pare, et al.
Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case-control echocardiographic study
Europace,
May 1, 2007;
9(5):
294 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Nussmeier, M. R. Marino, and W. K. Vaughn
Hormone replacement therapy is associated with improved survival in women undergoing coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg.,
December 1, 2002;
124(6):
1225 - 1229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N.A. Nussmeier, W.Y. Thong, M.R. Marino, C.L. Williams, and W.K. Vaughn
Hormone replacement therapy improves the survival of women undergoing coronary artery bypass grafting
Ann. Thorac. Surg.,
January 1, 2002;
73(1):
S371 - 371.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Ryan, B. J. Nicklas, and D. M. Berman
Hormone Replacement Therapy, Insulin Sensitivity, and Abdominal Obesity in Postmenopausal Women
Diabetes Care,
January 1, 2002;
25(1):
127 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Shlipak, B. G. Angeja, A. S. Go, P. D. Frederick, J. G. Canto, and D. Grady
Hormone Therapy and In-Hospital Survival After Myocardial Infarction in Postmenopausal Women
Circulation,
November 6, 2001;
104(19):
2300 - 2304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Sharma, M. V. Gurjar, and R. C. Bhalla
Genome and Hormones: Gender Differences in Physiology: Selected Contribution: Estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappa B activation in VSM cells from female rats
J Appl Physiol,
November 1, 2001;
91(5):
2400 - 2406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. LaRosa
Prevention and Treatment of Coronary Heart Disease: Who Benefits?
Circulation,
October 2, 2001;
104(14):
1688 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grodstein, J. E. Manson, and M. J. Stampfer
Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study
Ann Intern Med,
July 3, 2001;
135(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ling, G. Deng, H. E. Ives, K. Chatterjee, G. M. Rubanyi, P. A. Komesaroff, and K. Sudhir
Estrogen inhibits mechanical strain-induced mitogenesis in human vascular smooth muscle cells via down-regulation of Sp-1
Cardiovasc Res,
April 1, 2001;
50(1):
108 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay
Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model
J. Am. Coll. Cardiol.,
November 15, 2000;
36(6):
1972 - 1978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Geary, D. N. Krause, and S. P. Duckles
Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms
Am J Physiol Heart Circ Physiol,
August 1, 2000;
279(2):
H610 - H618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. McNulty, D. Jagasia, J. M. Whiting, and T. Caulin-Glaser
Effect of 6-wk estrogen withdrawal or replacement on myocardial ischemic tolerance in rats
Am J Physiol Heart Circ Physiol,
April 1, 2000;
278(4):
H1030 - H1034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hugel, M. Reincke, H. Stromer, J. Winning, M. Horn, C. Dienesch, P. Mora, H. H. H. W. Schmidt, B. Allolio, and S. Neubauer
Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling
J. Am. Coll. Cardiol.,
November 1, 1999;
34(5):
1427 - 1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Wise, D. E. Stewart, P. Liu, and B. L. Abramson
Use of hormone replacement therapy among cardiac patients at a Canadian academic centre
Can. Med. Assoc. J.,
July 13, 1999;
161(1):
33 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Grover
Estrogen replacement for women with cardiovascular disease: Why don't physicians and patients follow the guidelines?
Can. Med. Assoc. J.,
July 13, 1999;
161(1):
42 - 43.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. E. Heidland, M. P. Heintzen, W. J. Klimek, C. J. Michel, and B. E. Strauer
Acute Complications and Restenosis in Women Undergoing Percutaneous Transluminal Coronary Angioplasty. Is it Possible to Define Sex Differences and to Determine Risk Factors?
European Journal of Cardiovascular Prevention & Rehabilitation,
October 1, 1998;
5(5-6):
297 - 302.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff, and for the Heart and Estrogen/progestin Replacement S
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
JAMA,
August 19, 1998;
280(7):
605 - 613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Petitti
Hormone Replacement Therapy and Heart Disease Prevention: Experimentation Trumps Observation
JAMA,
August 19, 1998;
280(7):
650 - 652.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Edwards, J. S. Carey, F. L. Grover, J. W. Bero, and R. S. Hartz
Impact of gender on coronary bypass operative mortality
Ann. Thorac. Surg.,
July 1, 1998;
66(1):
125 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Selzman, T. A. Whitehill, B. D. Shames, E. J. Pulido, B. C. Cain, and A. H. Harken
The Biology of Estrogen-Mediated Repair of Cardiovascular Injury
Ann. Thorac. Surg.,
March 1, 1998;
65(3):
868 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Estrogens Improve Outcome After PTCA
Journal Watch Cardiology,
January 27, 1997;
1997(127):
3 - 3.
[Full Text]
|
|
|
|
|
|
|
HRT MAY IMPROVE OUTCOMES AFTER ANGIOPLASTY
Journal Watch (General),
January 24, 1997;
1997(124):
2 - 2.
[Full Text]
|
|
|
|
